Krystal Biotech, Inc. Share-based Payment Arrangement, Expense
Krystal Biotech, Inc. (KRYS) reported Share-based Payment Arrangement, Expense of $14.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-03
- Krystal Biotech, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $14.16M, a 0.26% increase year-over-year.
- Krystal Biotech, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $13.61M, a 0.97% increase year-over-year.
- Krystal Biotech, Inc. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $14.12M.
- Krystal Biotech, Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $13.48M.
- Krystal Biotech, Inc. share-based payment arrangement, expense for fiscal 2025 was $54.51M, a 10.97% increase from fiscal 2024.
- Krystal Biotech, Inc. share-based payment arrangement, expense for fiscal 2024 was $49.13M, a 23.02% increase from fiscal 2023.
- Krystal Biotech, Inc. share-based payment arrangement, expense for fiscal 2023 was $39.93M, a 26.98% increase from fiscal 2022.
- Krystal Biotech, Inc. share-based payment arrangement, expense for fiscal 2022 was $31.45M, a 130.07% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.16M 10-Q · filed 2026-08-03 | $27.77M 10-Q · filed 2026-08-03 | |||||
| 2026-03-31 | $13.61M 10-Q · filed 2026-05-04 | ||||||
| 2025-12-31 | $54.51M 10-K · filed 2026-02-17 | ||||||
| 2025-06-30 | $14.12M 10-Q · filed 2026-08-03 | $27.60M 10-Q · filed 2026-08-03 | |||||
| 2025-03-31 | $13.48M 10-Q · filed 2026-05-04 | ||||||
| 2024-12-31 | $49.13M 10-K · filed 2026-02-17 | ||||||
| 2023-12-31 | $39.93M 10-K · filed 2026-02-17 | ||||||
| 2022-12-31 | $31.45M 10-K · filed 2023-02-27 | ||||||
| 2021-12-31 | $13.67M 10-K · filed 2023-02-27 | ||||||
| 2021-06-30 | $5.84M 10-Q · filed 2021-08-09 | ||||||
| 2020-12-31 | $570.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.93M derived: sum of 2 quarters · filed 2023-02-27 | $2.73M derived: sum of 3 quarters · filed 2023-02-27 | $3.27M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $1.36M 10-Q · filed 2020-11-09 | $2.16M derived: sum of 2 quarters · filed 2020-11-09 | $2.70M 10-Q · filed 2020-11-09 | $3.02M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2020-06-30 | $807.00K 10-Q · filed 2020-08-07 | $1.35M 10-Q · filed 2021-08-09 | $1.67M derived: sum of 3 quarters · filed 2021-03-01 | $1.95M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2020-03-31 | $539.00K 10-Q · filed 2020-05-04 | $862.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.14M derived: sum of 3 quarters · filed 2021-03-01 | $1.47M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $601.00K derived: sum of 2 quarters · filed 2021-03-01 | $926.00K derived: sum of 3 quarters · filed 2021-03-01 | $1.24M 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $278.00K 10-Q · filed 2020-11-09 | $603.00K derived: sum of 2 quarters · filed 2020-11-09 | $916.00K 10-Q · filed 2020-11-09 | $734.00K 10-Q · filed 2019-11-04 | $1.36M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $325.00K 10-Q · filed 2020-08-07 | $252.00K 10-Q · filed 2019-08-05 | $638.00K 10-Q · filed 2020-08-07 | $456.00K 10-Q · filed 2019-08-05 | $1.09M derived: sum of 3 quarters · filed 2020-08-07 | $1.25M derived: sum of 4 quarters · filed 2020-08-07 | |
| 2019-03-31 | $313.00K 10-Q · filed 2020-05-04 | $204.00K 10-Q · filed 2019-05-07 | $761.00K derived: sum of 2 quarters · filed 2020-05-04 | $929.00K derived: sum of 3 quarters · filed 2020-05-04 | $1.04M derived: sum of 4 quarters · filed 2020-05-04 | ||
| 2018-12-31 | $448.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $616.00K derived: sum of 2 quarters · filed 2020-03-10 | $726.00K derived: sum of 3 quarters · filed 2020-03-10 | $792.00K 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $168.00K 10-Q · filed 2019-11-04 | $278.00K derived: sum of 2 quarters · filed 2019-11-04 | $344.00K 10-Q · filed 2019-11-04 | $401.00K derived: sum of 4 quarters · filed 2019-11-04 | |||
| 2018-06-30 | $110.00K 10-Q · filed 2019-08-05 | $175.00K 10-Q · filed 2019-08-05 | $233.00K derived: sum of 3 quarters · filed 2019-08-05 | $287.00K derived: sum of 4 quarters · filed 2019-08-05 | |||
| 2018-03-31 | $65.00K 10-Q · filed 2019-05-07 | $123.00K derived: sum of 2 quarters · filed 2019-05-07 | $177.00K derived: sum of 3 quarters · filed 2019-05-07 | $221.00K derived: sum of 4 quarters · filed 2019-05-07 | |||
| 2017-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $112.00K derived: sum of 2 quarters · filed 2018-11-05 | $156.00K derived: sum of 3 quarters · filed 2018-11-05 | $246.00K 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $54.00K 10-Q · filed 2018-11-05 | $98.00K derived: sum of 2 quarters · filed 2018-11-05 | $188.00K 10-Q · filed 2018-11-05 | $189.00K derived: sum of 4 quarters · filed 2018-11-05 | |||
| 2017-06-30 | $44.00K 10-Q · filed 2018-08-06 | $135.00K 10-Q · filed 2018-08-06 | $135.00K derived: sum of 3 quarters · filed 2018-08-06 | $139.00K derived: sum of 4 quarters · filed 2018-08-06 | |||
| 2017-03-31 | $65.00K 10-Q · filed 2018-05-07 | $91.00K derived: sum of 2 quarters · filed 2018-05-07 | $95.00K derived: sum of 3 quarters · filed 2018-05-07 | ||||
| 2016-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $30.00K derived: sum of 2 quarters · filed 2018-03-12 | $33.00K 10-K · filed 2018-03-12 | ||||
| 2016-09-30 | $4.00K 10-Q · filed 2017-11-13 | $7.00K 10-Q · filed 2017-11-13 | |||||
| 2016-03-31 | $91.00K 10-Q · filed 2018-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |